Carly Newton: Closing the Gap in Sickle Cell Disease Readmissions
Carly Newton, Sr Manager of Apheresis Clinical Marketing at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“1 in 3 adults with sickle cell disease are back in the hospital within 30 days of discharge. For some young adults, it’s closer to 40%.
Behind every one of those readmissions is another crisis, more missed work or school, more strain on a family.
The data is consistent: transfusion therapy, especially automated red blood cell exchange (aRBCX), lowers that risk, even for the sickest patients. Yet fewer than 3% of SCD patients access RBCX each year, despite most having the access and prescriber support to get it.
This September, for National Sickle Cell Awareness Month, I’m breaking down why that gap exists and what closing it could mean for the people living this every day.
Read the full article on my Substack.”
Stay updated withΒ Hemostasis Today.
-
Sep 15, 2026, 17:33Reza Shojaei: Blood and Plasma Donors Are Not a Production Metric
-
Sep 15, 2026, 17:32Thomas Dayspring: MHT for Vasomotor Symptoms May Also Offer Cardiovascular Benefits
-
Sep 15, 2026, 17:31Rebecca Risman: Deciphering the Mechanisms of Fibrinolysis in Contracted Clots
-
Sep 15, 2026, 17:31Clare Tower: 30 Times Higher Does Not Tell the Whole Story
-
Sep 15, 2026, 17:29Erica Wood: Looking Forward to the Webinar on Future Directions in Haemovigilance
-
Sep 15, 2026, 17:28Caitlin Raymond: Can an Antibody Screen Tell You If a Transfusion Will Actually Hurt Your Patient?
-
Sep 15, 2026, 17:28Rachel Margolis-Goodman: When Conventional Treatment Could Not, Research Found an Answer
-
Sep 15, 2026, 17:26Jared Rice: Understanding Extreme Platelet Counts in Preterm Infants
-
Sep 15, 2026, 17:25Gregg W. Stone: OCT-Guided PCI Reduces Stent Thrombosis in Patients With Diabetes